Personalised medicine – often, and more precisely, called stratified medicine – is defined as the tailoring of medical treatment to a group of patients based on data from genetic or other biomarkers. It is growing in utility and popularity and has potential applications in many therapeutic areas. Almost certainly, however, it is in cancer treatment where the personalised approach is currently most widely used.
The well-established and successful drugs imatinib (Glivec®) and trastuzumab (Herceptin®) were developed to treat subsets of patients, those carrying the Philadelphia chromosome translocation and those over-expressing the HER2 receptor respectively. It is therefore hardly surprising that oncology drugs and their development featured extensively in a recent, prestigious meeting in this area, Personalised Medicine and Diagnostics Europe, held in London on March 9 and 10.
Personalised Medicine and Diagnostics Europe was organised by the UK division of pharmaceutical events and information company eyeforpharma. During the two days, a total of 19 speakers drawn from industry, clinical research and regulatory affairs discussed many aspects of the development, registration and use of drugs for stratified patient populations and their associated diagnostic tests.
You can read the full ecancer review of this important meeting here